Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Immunology
Factor de Impacto: 1.404 Factor de Impacto de 5 años: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN En Línea: 2162-6472

Volumes:
Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v25.i3.20
pages 183-214

iNKT-Cell Responses to Glycolipids

Vrajesh V. Parekh
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232
Michael T. Wilson
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232
Luc Van Kaer
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232

SINOPSIS

Invariant natural killer T (iNKT) cells are an unusual group of T lymphocytes that recognize glycolipid antigens presented by the major histocompatibility complex class I-related protein CD1d. Because iNKT cells play a regulatory role in the immune system, they are attractive targets for immunotherapy. The marine-sponge-derived glycolipid α-galactosylceramide (α-GalCer) potently activates iNKT cells. In vivo administration of α-GalCer to mice or humans results in rapid and robust cytokine secretion by iNKT cells, followed by the activation of a variety of cell types of the innate and adaptive immune systems. These potent immunomodulatory activities of α-GalCer are being exploited for therapeutic purposes. Preclinical studies in mice have demonstrated that α-GalCer and related glycolipids can protect mice against a variety of diseases, including cancer, infections, and several autoimmune and inflammatory conditions. Although α-GalCer treatment of mice is associated with unwanted side-effects, it has been proven safe in clinical trials with cancer patients. These studies have raised significant enthusiasm for the development of effective and safe iNKT-cell-based immunotherapies for a variety of human diseases.


Articles with similar content:

Improving Immunotherapy by Conditionally Enhancing MHC Class I Presentation of Tumor Antigen-Derived Peptide Epitopes
Critical Reviews™ in Immunology, Vol.27, 2007, issue 5
Ronald M. Bukowski, Mayumi Kawabe, Peter A. Cohen, James H. Finke, Amy K. Wesa, Walter J. Storkus, Christopher Herrem
IL-21 Is an Immune Activator That also Mediates Suppression via IL-10
Critical Reviews™ in Immunology, Vol.30, 2010, issue 6
Warren J. Leonard, Rosanne Spolski
Multiple Defects of Natural Killer Cells in Cancer Patients: Anarchy, Dysregulated Systemic Immunity, and Immunosuppression in Metastatic Cancer
Critical Reviews™ in Immunology, Vol.40, 2020, issue 2
Tamara Lah Turnsek, Barbara Breznik, Meng-Wei Ko, Kristin Y. Nguyen, Janko Kos, Kawaljit Kaur, Anahid Jewett, Paul Wong, Emanuela Senjor
Therapeutic Dendritic Cell−Based Cancer Vaccines: The State of the Art
Critical Reviews™ in Immunology, Vol.33, 2013, issue 6
Marius M. Strioga, Valerijus Ostapenko, Daniel J. Powell Jr., Neringa T. Dobrovolskiene, Virgil E. J. C. Schijns, Thomas Felzmann, Jaroslav Michalek, Miroslava Matuskova
Immunopathogenesis of the Anti-Synthetase Syndrome
Critical Reviews™ in Immunology, Vol.38, 2018, issue 4
Yurdagül Uzunhan, Baptiste Hervier, Vincent Vieillard, Catherine Gayed, Isabelle Cremer